Public Profile

Padagis US LLC

Padagis US LLC, headquartered in the United States, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality generic and specialty medications. Founded in 2018, the company has quickly established itself as a trusted provider, focusing on areas such as injectables and complex formulations. With a commitment to innovation, Padagis offers a diverse portfolio of products that stand out for their quality and efficacy. The company operates primarily in the US market, with a growing presence in international regions. Notable achievements include securing multiple FDA approvals, which underscore its dedication to meeting stringent regulatory standards. As a result, Padagis US LLC is well-positioned to contribute significantly to the healthcare landscape, ensuring access to essential medications for patients across various therapeutic areas.

DitchCarbon Score

How does Padagis US LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Padagis US LLC's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

46%

Let us know if this data was useful to you

Padagis US LLC's reported carbon emissions

Padagis US LLC, headquartered in the United States, currently does not have available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of concrete data, it is essential for Padagis US LLC to establish clear climate commitments and reduction strategies to align with industry standards and expectations for sustainability.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Padagis US LLC's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Padagis US LLC is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Padagis US LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Innopharma, Inc.

US
Research and development services (73)
Updated 4 months ago
DitchCarbon Score

Fresenius Kabi Aktiengesellschaft

DE
Real estate services (70)
Updated 4 months ago
DitchCarbon Score

Sanofi

FR
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Akorn

US
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Sagent Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers